Redefining Surgical Standards: The Case Against Routine Mediastinal Lymph Node Dissection in Ground Glass Opacity-Dominant Lung Adenocarcinoma

Early Trial Termination Signals a Paradigm Shift Toward Precision Surgery in Early-Stage Lung Cancer

TribeMD

4 min read

July 28, 2025

Carregando conteúdo…

Oncology

Sources

Zhang, Y., et al. (2025). Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma. Journal of Clinical Oncology, 00, 1-9.

Highlights

ASCO GU® 2026

Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer

SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care